Nomograms to predict survival rates for esophageal cancer patients with malignant behaviors based on ICD-0-3

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review: 1975–2013, National Cancer Institute (2016). http://seer.cancer.gov/csr/1975_2013/.
  Google Scholar
• 2 Yendamuri S, Malhotra U, Hennon M et al. Clinical characteristics of adenosquamous esophageal carcinoma. J. Gastrointest. Oncol. 8(1), 89–95 (2016).
  Google Scholar
• 3 Cao J, Yuan P, Wang L et al. Clinical nomogram for predicting survival of esophageal cancer patients after esophagectomy. Sci. Rep. 24(6), 26684 (2016).
  Google Scholar
• 4 Matsumoto S1, Takayama T, Tamamoto T et al. A comparison of surgery and radiation therapy for cT1 esophageal squamous cell carcinoma. Dis. Esophagus 24(6), 411–417 (2011).
  Medline CASGoogle Scholar
• 5 Kukar M, Groman A, Malhotra U et al. Small cell carcinoma of the esophagus: a SEER database analysis. Ann. Surg. Oncol. 20(13), 4239–4244 (2013).
  MedlineGoogle Scholar
• 6 Merkow RP, Bilimoria KY, McCarter MD et al. Effect of histologic subtype on treatment and outcomes for esophageal cancer in the United States. Cancer 118(13), 3268–3276 (2012). •• Provided important evidence that the trend and effect of current treatments were different between adenocarcinoma and squamous carcinoma.
  MedlineGoogle Scholar
• 7 Bollschweiler E, Hölscher AH, Metzger R. Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. Future Oncol. 6(1), 25–35 (2010). •• Provided evidence that squamous carcinoma and adenocarcinoma responded differently to neoadjuvant therapy.
  CASGoogle Scholar
• 8 Vickers AJ, Cronin AM, Elkin EB et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med. Inform. Decis. Mak. 8(1), 53 (2008).
  MedlineGoogle Scholar
• 9 Eil R, Diggs BS, Wang SJ et al. Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for patients with esophageal cancer: a SEER-Medicare analysis. Cancer 120(4), 492–498 (2014). • Provided evidence that T4 patients could benefit a lot from neoadjuvant chemoradiotherapy.
  MedlineGoogle Scholar
• 10 Wu WC, Wang Y, Wang X et al. Clinical analysis of acute lung injury after esophagectomy. J. Cancer Res. Ther. 10(Suppl.), 314–318 (2014).
  MedlineGoogle Scholar
• 11 Berry MF, Zeyer-Brunner J, Castleberry AW et al. Treatment modalities for T1N0 esophageal cancers: a comparative analysis of local therapy versus surgical resection. J. Thorac. Oncol. 8(6), 796–802 (2013).
  MedlineGoogle Scholar
• 12 Rizk NP, Ishwaran H, Rice TW et al. Optimum lymphadenectomy for esophageal cancer. Ann. Surg. 251(1), 46–50 (2010).
  MedlineGoogle Scholar
• 13 Lagarde SM, Reitsma JB, de Castro SM et al. Prognostic nomogram for patients undergoing oesophagectomy for adenocarcinoma of the oesophagus or gastro-oesophageal junction. Br. J. Surg. 94(11), 1361–1368 (2007).
  Medline CASGoogle Scholar
• 14 Wojcieszynski AP, Berman AT, Wan F et al. The impact of radiation therapy sequencing on survival and cardiopulmonary mortality in the combined modality treatment of patients with esophageal cancer. Cancer 119(11), 1976–1984 (2013). • Provided evidence that patients who received preoperative radiation had better prognosis than patients who received postoperative radiation.
  MedlineGoogle Scholar
• 15 van Hagen P1, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366(22), 2074–2084 (2012). • Found that preoperative chemoradiotherapy could improve overall survival and supported the use of preoperative chemoradiotherapy in esophageal cancer patients.
  Medline CASGoogle Scholar
• 16 Worni M, Castleberry AW, Gloor B et al. Trends and outcomes in the use of surgery and radiation for the treatment of locally advanced esophageal cancer: a propensity score adjusted analysis of the surveillance, epidemiology and end results registry from 1998 to 2008. Dis. Esophagus 27(7), 662–669 (2014).
  Medline CASGoogle Scholar
• 17 Chen YH, Huang CH. Esophageal squamous cell carcinoma with dural and bone marrow metastases. World J. Gastroenterol. 20(35), 12691–12695 (2014).
  MedlineGoogle Scholar
• 18 Depypere L, Lerut T, Moons J et al. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road. Dis. Esophagus 30(1), 1–8 (2017).
  Medline CASGoogle Scholar
• 19 Kothari N, Mellon E, Hoffe SE et al. Outcomes in patients with brain metastasis from esophageal carcinoma. J. Gastrointest. Oncol. 7(4), 562–569 (2016).
  MedlineGoogle Scholar
• 20 Esmaeilzadeh M, Majlesara A, Faridar A et al. Brain metastasis from gastrointestinal cancers: a systematic review. Int. J. Clin. Pract. 68(7), 890–899 (2014).
  Medline CASGoogle Scholar
• 21 Feng W, Zhang P, Zheng X, Chen M, Mao WM.Incidence and treatment of brain metastasis in patients with esophageal carcinoma. World J. Gastroenterol. 21(19), 5805–5812 (2015).
  Medline CASGoogle Scholar
• 22 Niu J, Gelbspan D, Weitz D et al. HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report. J. Gastrointest. Oncol. 5(6), E103–E108 (2014).
  MedlineGoogle Scholar
• 23 Song Z, Lin B, Shao L et al. Brain metastases from esophageal cancer: clinical review of 26 cases. World Neurosurg. 81(1), 131–135 (2014).
  MedlineGoogle Scholar